Effects of single- and multiple-dose oxytocin treatment on amygdala low-frequency BOLD fluctuations and BOLD spectral dynamics in autism.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
20 09 2022
20 09 2022
Historique:
received:
24
03
2022
accepted:
07
09
2022
revised:
02
09
2022
entrez:
20
9
2022
pubmed:
21
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Prior neuroimaging clinical trials investigating the neural effects of intranasal administration of the neuropeptide oxytocin demonstrated a key role of the amygdala in oxytocin's neuromodulatory effects. These studies mostly demonstrated the acute effects of single-dose administrations, examining task-dependent effects of oxytocin on brain activity elicited during explicit experimental tasks or stimuli presentations. The increased consideration of oxytocin as a potential ameliorating treatment in autism spectrum disorder (ASD) requires a better understanding of how multiple-dose oxytocin administration affects intrinsic, task-free, amygdala function. In this double-blind, randomized, placebo-controlled trial with between-subject design, 38 adult men with ASD underwent resting-state fMRI scanning before and after oxytocin or placebo treatment. Effects were assessed either after a single-dose administration, consisting of 24 international units, or after multiple-dose treatment, consisting of 4 weeks of once-daily nasal spray administrations. Compared to placebo, oxytocin induced a decrease in intrinsic resting-state BOLD signal amplitudes of the bilateral amygdala (fractional amplitudes of low-frequency fluctuations) and modulated cross-frequency interactions between adjacent BOLD frequency components. The right amygdala showed a pattern of reduced cross-frequency harmonicity, while the left amygdala showed a relative increase in harmonic cross-frequency interactions after oxytocin treatment. Notably, the direction and magnitude of BOLD spectral changes induced after a single-dose were qualitatively similar to treatment effects induced after multiple-dose treatment. Furthermore, the identified spectral changes in amygdalar BOLD amplitude and cross-frequency harmonicity were associated with improved feelings of tension, reflecting oxytocin's anxiolytic, stress-reducing neuromodulatory role. The observed effects of oxytocin on amygdalar BOLD spectral characteristics and associated behaviors contribute to a deeper mechanistic understanding of the intrinsic, task-free neuromodulatory dynamics that underlie single- and multiple-dose oxytocin treatment in ASD. European Clinical Trial Registry (Eudract 2014-000586-45).
Identifiants
pubmed: 36127337
doi: 10.1038/s41398-022-02158-8
pii: 10.1038/s41398-022-02158-8
pmc: PMC9489696
doi:
Substances chimiques
Anti-Anxiety Agents
0
Nasal Sprays
0
Neuropeptides
0
Oxytocin
50-56-6
Banques de données
EudraCT
['2014-000586-45']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
393Informations de copyright
© 2022. The Author(s).
Références
Eur J Neurosci. 2021 Mar;53(6):1855-1868
pubmed: 33289167
Transl Psychiatry. 2020 Nov 6;10(1):383
pubmed: 33159033
Psychother Psychosom. 2022;91(4):253-264
pubmed: 35086102
Sci Rep. 2021 Dec 8;11(1):23589
pubmed: 34880300
Transl Psychiatry. 2020 Jun 8;10(1):180
pubmed: 32513936
Neurosci Biobehav Rev. 2020 Jan;108:1-23
pubmed: 31647964
J Autism Dev Disord. 2014 Mar;44(3):521-31
pubmed: 23888359
Psychoneuroendocrinology. 2021 Nov;133:105397
pubmed: 34481326
Neuron. 2016 May 4;90(3):609-21
pubmed: 27112498
Neurosci Lett. 2019 Oct 15;711:134401
pubmed: 31349018
Psychol Med. 2020 Dec 04;:1-10
pubmed: 33272333
Biol Psychiatry. 2010 Mar 15;67(6):e33-4; author reply e35
pubmed: 20060102
Horm Behav. 2012 Mar;61(3):410-8
pubmed: 22265852
Science. 2005 Apr 8;308(5719):245-8
pubmed: 15821089
Neurosci Biobehav Rev. 2018 Dec;95:17-32
pubmed: 30243577
Trends Cogn Sci. 2011 Jul;15(7):301-9
pubmed: 21696997
J Neurophysiol. 2009 Oct;102(4):2253-64
pubmed: 19625541
Neuron. 2012 Oct 4;76(1):142-59
pubmed: 23040812
Neuroimage. 2021 Feb 15;227:117668
pubmed: 33359350
Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Jul;4(7):655-663
pubmed: 30846366
N Engl J Med. 2021 Oct 14;385(16):1462-1473
pubmed: 34644471
Front Hum Neurosci. 2013 Nov 12;7:766
pubmed: 24273507
Psychiatry Res Neuroimaging. 2018 Feb 28;272:17-29
pubmed: 29272737
J Psychiatry Neurosci. 2015 Jan;40(1):E1-22
pubmed: 25520163
Neuropsychopharmacology. 2020 Jun;45(7):1141-1149
pubmed: 32161366
Front Neurosci. 2019 Sep 04;13:900
pubmed: 31551676
Annu Rev Neurosci. 2015 Jul 8;38:369-88
pubmed: 26154981
Psychoneuroendocrinology. 2018 Oct;96:6-24
pubmed: 29879563
Neuroimage. 2008 Mar 1;40(1):308-17
pubmed: 18178105
Trends Cogn Sci. 2012 Dec;16(12):606-17
pubmed: 23141428
Prog Neurobiol. 2022 Apr;211:102239
pubmed: 35122880
Sci Rep. 2020 Mar 25;10(1):5419
pubmed: 32214173
Physiol Rev. 2001 Apr;81(2):629-83
pubmed: 11274341
Soc Cogn Affect Neurosci. 2017 Oct 1;12(10):1565-1573
pubmed: 29048602
Transl Psychiatry. 2013 May 21;3:e258
pubmed: 23695233
J Neurosci. 2019 Aug 7;39(32):6291-6298
pubmed: 31175211
Nature. 2013 Aug 22;500(7463):458-62
pubmed: 23913275
Brain Res. 2010 Jun 4;1335:91-102
pubmed: 20350536
Biol Psychiatry. 2016 Feb 1;79(3):194-202
pubmed: 26321019
Eur Neuropsychopharmacol. 2020 Oct;39:87-98
pubmed: 32868176
Eur J Neurosci. 2018 Oct;48(7):2431-2453
pubmed: 30281858
Brain. 2015 Nov;138(Pt 11):3400-12
pubmed: 26336909
Front Neurosci. 2008 Dec 15;2(2):145-54
pubmed: 19225587
Eur J Pain. 2020 May;24(5):945-955
pubmed: 32061140
Trends Cogn Sci. 2016 Feb;20(2):133-145
pubmed: 26616296
J Abnorm Psychol. 1964 Dec;69:620-7
pubmed: 14241709
Front Syst Neurosci. 2020 Apr 07;14:16
pubmed: 32317942
Psychoneuroendocrinology. 2013 May;38(5):612-25
pubmed: 23265311
Nat Rev Neurosci. 2011 Aug 19;12(9):524-38
pubmed: 21852800
Mol Autism. 2020 Jan 15;11(1):6
pubmed: 31969977